|Dr. Jayson Donald Alexander Dallas||Pres, CEO & Director||859.79k||N/A||1968|
|Mr. Eric H. Bjerkholt||Chief Financial Officer||589.17k||N/A||1960|
|Mr. Douglas T. Sheehy||Gen. Counsel & Sec.||539.88k||249.28k||1967|
|Dr. Stephen George Dilly||Special Advisor||308.93k||8.57M||1960|
|Dr. Daniel C. Adelman||Chief Medical Officer||611.93k||1.05M||1957|
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.
Aimmune Therapeutics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 8.